Lepu Biopharma Co., Ltd.

SEHK:2157 Stock Report

Market Cap: HK$11.7b

Lepu Biopharma Future Growth

Future criteria checks 0/6

Lepu Biopharma's earnings are forecast to decline at 59.1% per annum while its annual revenue is expected to grow at 7.3% per year. EPS is expected to decline by 57.7% per annum.

Key information

-59.1%

Earnings growth rate

-57.66%

EPS growth rate

Biotechs earnings growth44.2%
Revenue growth rate7.3%
Future return on equityn/a
Analyst coverage

Low

Last updated15 Sep 2025

Recent future growth updates

No updates

Recent updates

Lepu Biopharma Co., Ltd. (HKG:2157) May Have Run Too Fast Too Soon With Recent 29% Price Plummet

Sep 22
Lepu Biopharma Co., Ltd. (HKG:2157) May Have Run Too Fast Too Soon With Recent 29% Price Plummet

Optimistic Investors Push Lepu Biopharma Co., Ltd. (HKG:2157) Shares Up 92% But Growth Is Lacking

Aug 06
Optimistic Investors Push Lepu Biopharma Co., Ltd. (HKG:2157) Shares Up 92% But Growth Is Lacking

What Lepu Biopharma Co., Ltd.'s (HKG:2157) 30% Share Price Gain Is Not Telling You

Jun 20
What Lepu Biopharma Co., Ltd.'s (HKG:2157) 30% Share Price Gain Is Not Telling You

Lepu Biopharma Co., Ltd.'s (HKG:2157) 27% Price Boost Is Out Of Tune With Revenues

May 04
Lepu Biopharma Co., Ltd.'s (HKG:2157) 27% Price Boost Is Out Of Tune With Revenues

Lepu Biopharma (HKG:2157) Is Making Moderate Use Of Debt

Aug 23
Lepu Biopharma (HKG:2157) Is Making Moderate Use Of Debt

The Price Is Right For Lepu Biopharma Co., Ltd. (HKG:2157) Even After Diving 27%

Jul 18
The Price Is Right For Lepu Biopharma Co., Ltd. (HKG:2157) Even After Diving 27%

Lepu Biopharma Co., Ltd. (HKG:2157) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

Jun 03
Lepu Biopharma Co., Ltd. (HKG:2157) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

Revenues Not Telling The Story For Lepu Biopharma Co., Ltd. (HKG:2157) After Shares Rise 26%

Apr 15
Revenues Not Telling The Story For Lepu Biopharma Co., Ltd. (HKG:2157) After Shares Rise 26%

Earnings and Revenue Growth Forecasts

SEHK:2157 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027737-608N/A-2921
12/31/2026592-520N/A-3881
12/31/2025448-102N/A-21
6/30/2025700-177-130-35N/A
3/31/2025534-294-194-115N/A
12/31/2024368-411-258-196N/A
9/30/2024286-242-296-243N/A
6/30/2024205-73-333-290N/A
3/31/2024215-47-313-271N/A
12/31/2023225-22-292-251N/A
9/30/2023197-254-366-307N/A
6/30/2023169-487-440-364N/A
3/31/202392-588-518-422N/A
12/31/202216-689-596-481N/A
9/30/20228-766-617-471N/A
6/30/2022N/A-843-638-460N/A
3/31/2022N/A-927-740-541N/A
12/31/2021N/A-1,011-841-622N/A
12/31/2020N/A-582-734-423N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2157 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2157 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2157 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 2157's revenue (7.3% per year) is forecast to grow slower than the Hong Kong market (8.7% per year).

High Growth Revenue: 2157's revenue (7.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 2157's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/17 17:54
End of Day Share Price 2025/10/17 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lepu Biopharma Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hanyang HuangIndustrial Securities Co. Ltd.
Sean WuMorgan Stanley
Po Han LinMorgan Stanley